PTEN and prostate cancer: Although similar models have previously been published upon [10,45,46], to our knowledge this is the first report of a model which has been proven to be syngeneically engraftable and is driven by relevant genetic drivers to prostate cancer (Pten and trp53), and mirrors clinical response.